TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
News|Slideshows|August 9, 2023
Prescription "Weight Loss" Drugs: Americans Voice an Opinion
Author(s)Grace Halsey
Most Americans are aware of the hot prescription drugs associated with weight loss and many are interested in using them. But access and administration are problematic.
Advertisement
The explosion of media around the glucagon like peptide-1 (GLP-1) receptor agonist semaglutide , approved in 2017 as Ozempic for type 2 diabetes and most recently in 2021 as Wegovy for chronic weight management in adults with overweight/obesity shows no signs of abating. Both brand names have become synonymous with shedding pounds.
The most recent Kaiser Family Foundation (KFF) Health Tracking Poll gauged awareness of the weight loss drugs among a representative sample of US adults and asked them whether they had issues with weight and whether they would consider using a "weight loss" medication. Questions then turned to issues including how the drug is administered and insurance coverage and the level of interest in the proposed medications shifted.
Here is a topline look at the findings.
Advertisement
Related to this article
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Advertisement
Advertisement